NCT04267900View on ClinicalTrials.gov

99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

December 7, 2019

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Breast Cancer
Interventions
DRUG

99mTc-HPArk2

99mTc-HPArk2 were injected into the patients before the SPECT/CT scans

Trial Locations (1)

100730

Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT04267900 - 99mTc-HPArk2 SPECT/CT for the Detection of HER2-positive Breast Cancer | Biotech Hunter | Biotech Hunter